HDAC3 and acute myeloid leukemia: To evaluate a possible anti-leukemic effect of HDAC3 inhibition in vivo we utilized the SKNO1 leukemia model bearing a RUNX1-RUNX1T1 translocation and ELF-153 complex karyotype AML, which are both addicted to ERG expression25,50 (Fig. 8B) and dependent on HDAC3 activity (Fig. 9A).